Answers are grounded in this paper and cite their sources.
The aim is to evaluate the incidence of retinopathy of prematurity within three years in premature babies followed up in our clinic, to determine the risk factors that play a role in the development of retinopathy, to evaluate intravitreal ranibizumab treatment and its results. Methods: Babies with a birth weight of 32 weeks and/or a birth weight of 1500 grams and babies determined to be at risk by the clinician were examined for the development of retinopathy. Risk factors including week of birth, birth weight, mode of delivery, gender, APGAR scores, need for mechanical ventilation, 40% oxygen therapy, duration of oxygen therapy, surfactant therapy, acidosis, hypoxia, sepsis, erythrocyte transfusion, intraventricular hemorrhage, apnea and anemia were compared between cases who developed or did not develop retinopathy of prematurity. Results: The mean birth week of the babies was 30.10.24 weeks (23-36 weeks), and the mean birth weight was 1362.3378.6 grams (450-2020 grams). Retinopathy of prematurity at different stages was detected in 21 (16.2%) of 130 patients. Eight (6.1%) of all patients screened for retinopathy of prematurity required treatment. Intravitreal ranibizumab was administered to seven patients (5.3%) with Stage III retinopathy, and both ranibizumab and laser therapy were applied to one patient with Stage IV retinopathy. Week of birth and low birth weight (p<0.001), duration of oxygen therapy (p<0.001), receiving surfactant treatment (p=0.002), sepsis (p<0.001), blood transfusion (p<0.001), intraventricular haemorrhage (p=0.019), apnea (p<0.001), anemia (p<0.001), hypoxia (p<0.001), acidosis (p<0.001) and low APGAR score (p<0.001) were found to significantly decrease the risk of developing retinopathy of prematurity. Discussion and Conclusion: The development of retinopathy of prematurity can be reduced by appropriate management of risk factors that increase retinopathy of prematurity, such as low birth week and weight, high concentration and long-term oxygen use. Although there is no clear recommendation for the treatment of retinopathy of prematurity, it is thought that intravitreal ranibizumab treatment may be a good option in selected cases.
No takes yet. Share an insight, caveat, or question.
Baran Cengiz Arcagök (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: